Amorphous, Eosinophilic, and Acellular Deposit

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Amorphous, Eosinophilic, and Acellular Deposit trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT02685969

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional an…

Spain570 participantsStarted 2017-03-01

Treatment: 18F-Flutemetamol & 18F-FDG

All recent trials (10 shown)

CompletedNot Applicable

NCT03913637

Facilitating Optimal Routines in Aging

Loss of cognitive abilities leading to Alzheimer's disease is progressive and destructive, leaving older adults disabled and unable to recall their past. The nu…

United States105 participantsStarted 2019-07-31

Treatment: Strategy Training, Enhanced Usual Care

CompletedPhase 2

NCT03499808

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclo…

United States43 participantsStarted 2018-06-06

Treatment: Isatuximab, Laboratory Biomarker Analysis

Amorphous, Eosinophilic, and Acellular Deposit

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

All recent trials (10 shown)

Facilitating Optimal Routines in Aging

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

All recent trials (10 shown)

Facilitating Optimal Routines in Aging

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition

The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction in Alzheimer's Disease

Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects

Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease

Natural History of Amyloid Deposition in Adults With Down Syndrome

Implications of Amyloid Pathology